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Abstract 
Background: Oxaliplatin (OX) has been widely used for treatment of colorectal and 
other cancers. Adverse effect of OX and other anticancer agents on cognition have been 
reported, but studies on the effects of chemotherapy on brain structure are scarce. This 
study describes the morphometrical features of the hippocampus structures in rat 
following OX treatment using design-based stereological methods.  
Materials and methods: Ten male Wistar rats were randomized into two groups. The 
rats from OX group received 2.4 mg/kg OX in vehicle for five consecutive days every 
week for 2 weeks intraperitoneally (IP). Controls received vehicle only. Cavalieri 's 
method and the optical fractionator method were used for volume and neuron estimation, 
respectively.  
Results: Cavalieri 's method was used for to estimate volume and showed that the 
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volume of the hippocampus was significantly decreased in OX group (31.84 ± 1.24 
mm3) compared with the vehicle control group (36.95 ± 3.48 mm3). The optical 
fractionator method was used to estimate neuron number and showed that the number of 
neurons in dentate gyrus, cornu ammonis 1 and 3 in OX group (8.147 ± 2.84 × 105, 
4.257 ±  0.59 × 105 and 2.133 ± 0.22 × 105, respectively) did not differ from  those of 
vehicle control group (7.36 ± 1.42 × 105, 3.521 ± 0.54  × 105 and 1.989 ± 0.46 × 105, 
respectively).  
Conclusions: These findings suggested that OX treatment induce loss of hippocampal 
volume without neuronal loss which might help to clarify the mechanism by which OX 
affects cognition and to improve preventive treatment strategies.  
Key words: stereology, hippocampus, oxaliplatin, chemotherapy, rat 
 
 
 
Introduction 
Chemotherapy in many cancer types have increased survival times in patients. 
However, cognitive dysfunctions, referred to as “chemobrain”, such as impairments in 
attention and concentration, verbal and visual memory and processing speed have been 
reported after systemic chemotherapy [7,41]. There are numerous reports regarding 
adverse effect of different anticancer agents like methotrexate [29,37,42,46], 5-
fluorouracil [8,11], cyclophosphamide [9,36], doxorubicin [23,27], paclitaxel [19], 
vincristine [5,35] and cytosine arabinoside [26] on cognition in human and animal 
experimental models. Chemotherapy agents, which inhibit tumor cell proliferation, can 
also effect on non-tumor cell proliferation in the brain [7]. 
Oxaliplatin (OX) is a third-generation platinum drug which has been widely 
used alone or with other chemotherapeutic agents for treatment of colorectal cancer and 
other carcinomas including ovarian, breast and lung cancers  [34,40]. It is able to react 
with DNA to create DNA intrastrand adducts, which block DNA synthesis and induce 
apoptosis in cancer cells and rapidly dividing cells [43]. OX induces peripheral 
neuropathy [38], crosses the blood-brain barrier and accumulates in cerebrospinal and 
extracellular fluid in the brain [17,18], which indicates that the drug can have a direct 
effect on brain function and structure. Treatment with OX has been shown to induce 
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cognitive impairment in laboratory animals [9,10,39]. Furthermore, cellular damage in 
the hippocampus has been related to the loss of memory function in rats following OX 
administration [4,7]. Other platinum compounds such as cisplatin, have also been 
reported to produce cognitive dysfunction and central neurological problems [28,48].  
The hippocampus, as the key structure in learning and the formation of memory 
is an appropriate site for investigating the mechanisms involved in some of the 
cognitive problems arisen by the chemotherapeutic agents [4].  
Designed-base stereology enables unbiased and precise quantitative analysis of 
three-dimensional structures [15]. It is one of the important techniques for the 
morphometrical evaluation of the hippocampus, which contain important information 
about the memory function [14]. The morphometrical features of the hippocampus 
following chemotherapy have not been thoroughly investigated using stereology. 
Assessment of the effect of OX on hippocampus volume using Cavalieri 's method and 
neuronal number in different regions of the hippocampus using optical 
disector/fractionator, as a gold standard for efficient, unbiased number estimation in 
neuroscience, may contribute to evaluate the risks of the treatment and possibly help 
improve preventive strategies. 
 
MATERIALS AND METHODS 
Animals- Ten adult (12-15 weeks) male Wistar rats (Pasteur Institute, Tehran, 
Iran) were used for the experiment. Animals were housed in large acrylic cages with 
free access to food and water under controlled light (12 h light and dark cycle) and 
temperature (22 ±2 °C). The rats were allowed to acclimatize for one week before 
experimentation. 
All experimental procedures involving animals in this study were conducted in 
accordance with the standard guide for the care and use of laboratory animals of the 
University of Tehran, Tehran, Iran. 
Drug administration- Rats were randomly divided into OX-treated and vehicle 
control groups. The rats from OX group received 2.4 mg/kg OX dissolved in 5% 
glucose solution (vehicle) for five consecutive days per week for 2 weeks 
intraperitoneally (IP) and the vehicle control was administrated 5% glucose solution. 
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The chosen dose of OX was in accordance with that commonly used for neurotoxic 
evaluation of the agent in previous animal studies [4].  
Tissue sampling and stereological methods- Rats were euthanized 21 days after 
treatment using thiopental (50 mg/kg IP). Then, transcardial perfusion fixation of the 
animals was done using 10 % formalin. The brains were removed and the left 
hemisphere of each animal was fixed in same fixative, dehydrated and embedded in 
glycol methacrylate (Technovit 7100, Heraeus Kulzer GmbH, Wehrheim/Ts, Germany) 
according to the manufacturer's instructions.  
Embedded brains were cut frontally using a rotary microtome with 20 
micrometer thickness. Every 20th section was collected using the principle of 
systematic uniform random sampling, which is known as the section sampling fraction 
(ssf= 1/20). On average, this sampling scheme provided 13 (11-15) sections per animal. 
Sections were mounted, dried and stained in Giemsa solution [16].  
Hippocampal volume and principal cell numbers were estimated using 
StereoInvestigator 10 software (MBF Bioscience, Williston, VT, USA). The 
hippocampus including dentate gyrus (DG) and cornu ammonis (CA) were determined 
in the sections using rat brain atlas of Paxinos and Watson (1986). DG were recognized 
due to horseshoe-shape with small and densely packed neurons. The CA2 region in this 
study was considered as belong to the CA3 region because the CA2 is very small and 
the boundaries between these two regions are not detectable. The border between the 
CA3 and CA1 is defined by a small transition zone between the two regions [21] (Fig. 
1).   
Estimation of the volume- Estimation of total volume of the hippocampus was 
done using test points on each section (Fig. 2a). The volume was estimated by Cavalieri 
estimator using the following equation [15]: V= ΣP · ssf · T · (a/p) 
where ΣP is the total number of points hitting the structure; ssf (1/20) is the section 
sampling fraction; T (20 µm) is the section thickness and a/p (9·104 µm2) represents the 
area per point. 
Estimation of the number of neurons- The optical fractionator was used for 
number estimation of pyramidal cells and granular cells in CA and DG, respectively. 
First, the contours of the dentate gyrus and the CA1 and CA3 regions were delineated at 
low magnification. Then, selected regions were analyzed by systematic random 
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sampling at high magnification. A known fraction of the each section was assessed by 
moving the microscope motorized stage in regular step length in x and y directions and 
applying an unbiased counting frame sized to count the neurons of specific region (Fig. 
2b).  
For DG, a step length of 180 μm and counting frame size of 12 × 12 μm was 
used, for CA1 a step length of 240 μm and frame size of 20 × 20 μm, and for CA3 a 
step length of 190 μm and frame size of 24 × 24 was applied. The counting frame was 
focused through 10 μm of the section thickness, which corresponds to disector height. 
Section thickness was measured at every 4-5 sampling location.  
The total number of cells in the granular cells (DG) and pyramidal cells (CA1 
and CA3) in the left hemisphere was calculated using the following formula [6,32]: 
N= 1/SSF . 1/ASF . 1/HSF . ∑Q- 
where  HSF= h / tQ- 
for tQ-= ∑ti q-i / ∑q-i 
∑Q- : total count of particles sampled; SSF: the section sample fraction; ASF: the area 
sample fraction (frame size/ x,y step length); Hsf : the height sampling fraction; h: the 
dissector height (10 μm in this study); tQ-: the number-weighted mean section thickness; 
ti: the section thickness in the ith counting frame with a cell count of q
-
i in the disector.  
Statistical analysis- The coefficient of error (CE) of the volume and the number 
estimates was calculated as previously described [13]. T-test was used for statistical 
analysis. A value of p < 0.05 was considered significant. 
 
RESULTS 
The results showed that the volume of the hippocampus was significantly 
decreased after OX treatment compared with the vehicle control group (p < 0.05). The 
related volume of hippocampus in OX-treated and vehicle control group was 31.84 ± 
1.24 mm3 and 36.95 ± 3.48 mm3, respectively (Table 1). The number of neurons in DG, 
CA1 and CA3 did not show any significant difference between the two groups. The 
neuronal number of DG, CA1 and CA3 in the OX-treated group was estimated to be 
8.147 ± 2.84 × 105, 4.257 ±  0.59 × 105 and 2.133 ± 0.22 × 105 respectively, while the 
related neurons in vehicle control group accounted 7.36 ± 1.42 × 105, 3.521 ± 0.54  × 
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105 and 1.989 ± 0.46 × 105, respectively (Table 1). The CE2/CV2 ratios (Table 1) are 
typically > 0.5 indicating that group variances are dominated by the inter-animal 
differences with only minor contributions of measurement variance to the group 
variance. 
 
DISCUSSION 
The hippocampus is pivotal for learning and the formation of memory in the 
brain. Since the hippocampus shows various forms of plasticity, including the formation 
of new nerve cells in adult animals, it may be affected by the chemotherapeutic drugs 
leading to cognitive deficit [25].  
In the present study, stereological techniques were used for the quantification of 
volume and number of neurons of the hippocampus following OX treatment in rat. The 
results of the current experiment demonstrated that treatment with OX caused a 
reduction in total volume of the hippocampus. Considering that oxaliplatin penetrates 
the blood brain barrier and accumulates in the brain [17,18], an effect on the 
hippocampus is plausible and may explain memory impairment and other cognitive 
dysfunctions that have been found in previous studies using behavioral tests [9,10,39].  
Similar to our results, magnetic resonance imaging (MRI) studies showed a 
reduced hippocampus volume in breast cancer survivors exposed to chemotherapy 
[1,3,22].  In contrast, Yoshikawa  et al. [47], found no adverse effects of adjuvant 
chemotherapy on hippocampal volume in Japanese breast cancer survivors using MRI. 
They implied that brain regions other than the hippocampus, such as the prefrontal 
cortex, might be involved in memory impairment after chemotherapy. 
The neuron numbers did not show any significant loss of either granular cells of 
the DG or pyramidal cells of the CA1 and CA3 following OX treatment in rat. OX has 
been reported to induce apoptotic pathway in hippocampus with increasing caspase-3 
and caspase-9 [4]. Cyclophosphamide chemotherapy has been suggested to suppress 
hippocampal neurogenesis and interrupt hippocampal function in mice [45]. 
Methotrexate also showed inhibition of the formation of immature neurons in the 
hippocampus [12,44]. It is interesting that although hippocampal neuronal loss has been 
explained well in Alzheimer diseases, Joelving et al. [20] did not find any significant 
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loss of neuron in Parkinson's disease. Korbo et al. [24] also reported no loss of 
hippocampal neurons in non-Alzheimer dementia. 
It should be mentioned that reduction in the number of neurons is not the only 
mechanism that affect neuronal function. Structurally, decreasing dendritic branching or 
losing synapses may impair neuronal function without neuronal loss [1]. Changes in 
hippocampal transmitters and signal transduction pathways are other mechanisms that 
may disturb hippocampal function [30,31]. These findings suggest that cognitive 
disorders may be associated with a variety of changes that may not necessarily include a 
change in neuronal cell number [20].  
It is important to note that the estimating neuron number based on 2-D counting 
is potentially biased. In our study, the potential bias was avoided by the use of the 
optical fractionator, which is a combination of fractionator sampling and the optical 
disector principle. This unbiased stereological method is not influenced by tissue 
deformation like shrinkage or swelling. Importantly, it is also unaffected by changes in 
the shape or size of the cells that are being counted. The optical fractionator is the gold-
standard method for estimating number of neurons [14,24].  
This study is the first description of an effect of oxaliplatin on the rat 
hippocampus using stereology. In conclusion, the results of the present study showed 
that OX treatment induces a decrease of hippocampal volume without neuronal loss. 
These findings might help to clarify the mechanism by which OX affects cognition by 
crossing the blood-brain barrier and accumulating in cerebrospinal and extracellular 
fluid in the brain and promote the development of treatment strategies that minimize 
cognitive side effects.  
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Table 1. Estimated hippocampal volume and neuron number.  
 OX-treated group Vehicle treated group p value 
 Mean ± SD CE CV Mean ± SD CE CV  
Total volume (mm3) 31.84 ± 1.24a 0.02 0.03 36.95 ± 3.48b 0.02 0.09 0.01 
Granular cell number (105) 7.36 ± 1.42 0.11 0.19 8.147 ± 2.84 0.11 0.34 0.69 
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Pyramidal cell number in CA1 (105) 3.521 ± 0.54   0.11 0.15 4.257 ±  0.59 0.1 0.13 0.19 
Pyramidal cell number in CA3 (105) 1.989 ± 0.46 0.12 0.23 2.133 ± 0.22 0.12 0.1 0.33 
Mean ± SD of hippocampal volume and neurons from one hemisphere (five animals in each group) 
estimates with CE (= SEM/mean; intera-animal coefficient of error) and CV (= SD/mean; observed inter-
animal coefficient of variation). Different superscript letters in the same rows indicate a significant 
difference, p < 0.05.  
 
 
 
Figure 1. Histological coronal section of the hippocampus (scale bar= 200 µm) with 
magnification of the CA1, CA3 and DG (scale bar= 500 µm). Arrowhead mark 
boundary between CA1 and CA3. 
 
Figure 2. Stereological method for estimating hippocampal volume and neuronal 
number. (a): Example of a point grid on histological section of the hippocampus. The 
total number of points hitting the whole hippocampus was counted. (b): Example of a 
unbiased counting frame used for optical dissector method. The cells which their 
nucleolus came into focus within dissector 's height if they were completely inside the 
counting frame or touched the accepted lines (green lines) were counted. Here one 
neuron (asterisk) was counted (scale bar= 200 µm).  
 


